Navigation Links
Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
Date:5/30/2012

MORRISTOWN, N.J., May 30, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Nifedipine Extended-Release Tablets, USP, 90mg, a generic equivalent to Bayer's Adalat® CC.  Distribution of the product has commenced. 

Nifedipine Extended-Release Tablets, USP, 90mg has sales of approximately $23 million for the 12 months ending December 31, 2011, according to IMS Health.   

Commenting on the new approval, Mike Perfetto, Vice President of Sales & Marketing of Actavis Inc, said:

"The launch of Nifedipine Extended-Release Tablets, USP 90mg complements the Nifedipine Extended-Release 30mg and 60 mg tablets that we currently market.  It is yet another example of Actavis' expertise in developing complex extended release products."

About Actavis:
Actavis Inc. is the U.S. subsidiary of Actavis Group hf.  Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

Adalat® CC is a registered trademark of a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.

 


'/>"/>
SOURCE Actavis Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
2. Watson to Acquire Actavis Group for EUR4.25 Billion
3. QRxPharma Signs License and Option Agreement with Actavis
4. Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity
5. Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion
6. Actavis to Launch Novel Pain Medication in the US
7. QRxPharma Announces Strategic Partnership with Actavis
8. Actavis Launches Generic KADIAN® Capsules in the U.S.
9. Actavis Plans Latin America Expansion
10. Actavis Launches Generic Keppra XR® Tablets in the U.S.
11. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... JOLLA, Calif. , Dec. 6, 2016 /PRNewswire/ ... a biopharmaceutical company leading the discovery and development ... new drug development candidates at its R&D day, ... The first candidate, RGLS5040, is an anti-miR targeting ... The second candidate, RGLS4326, is an anti-miR targeting ...
(Date:12/6/2016)... new study released today by the Alliance for ... Drug Pricing Program will continue to expand at an unprecedented ... exceed $23 billion in total purchases at the 340B price. ... Part B drug reimbursement purchases over the next five years. ... of data on total drug purchases through 340B from 2005 ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... ODU, a worldwide leader in ... its advanced highly customizable contact technology solutions. , ODU Single Contact Technology portfolio ... ideal for a wide range of applications that require customization from industries like ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving ... are not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. ... to the children of the world. , In exchange for generous donations, customers will ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Facial plastic surgeon, ... holiday season by donating a portion of proceeds to two local organizations: North Chicago ... Animal Control & Friends is a team of authorized and trained volunteers who ...
(Date:12/7/2016)... , ... December 07, 2016 , ... "ProBrand Flip allows ... all media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip ... to use drop zones. Editors can select from a variety of flip book animations. ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a ... to the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation ... she can for this country. , Nancy attributes her patriotic nature to her WWII ...
Breaking Medicine News(10 mins):